REG - OptiBiotix Health - Launch of SlimBiome products with US partner

OptiBiotix HealthAnnouncement

20/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250520:nRST2916Ja&default-theme=true

RNS Number : 2916J  OptiBiotix Health PLC  20 May 2025

OptiBiotix Health plc

("OptiBiotix" or the "Company" or "the Group")

 

Launch of SlimBiome® products with NASDAQ listed US partner

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
products which reduce hunger and food cravings, enhance the gut microbiome,
and sweet fibres as healthy sugar substitutes, announces the launch of
products containing SlimBiome® with a NASDAQ listed partner, Natural Health
Trends Corp (NASDAQ: NHTC) ("NHT").

 

NHT is an international direct selling and ecommerce company operating through
its subsidiaries throughout Asia, the Americas, and Europe.  The Company
markets premium quality products under the NHT global brand.  The product,
which was produced and shipped in final product format by OptiBiotix is a
Tomato Soup formulation,  TwinSlim Tomato Soup
(https://en.nhtglobal.com.hk/blog/products/twinslim-tomato-soup/?agreePrivacy=1)
, developed specifically for NHT and its global markets.  The product has
been launched in Hong Kong for the Chinese market with the product shipped for
launch in the USA in the upcoming weeks.  OptiBiotix has been involved in
presentations to NHT's Asian distributors and filming videos explaining the
science and benefits of SlimBiome® for both the Asian and USA markets.

 

This is the second USA partner launching SlimBiome® products in the last few
months, with a third, one of the USA's leading weight management brands,
expected to launch in the near future.  This is all part of the Company's
strategy to develop and market clinically proven and patented products with
functional benefits (for SlimBiome®: reduce hunger and food cravings) and
grow our business in the high growth markets of Asia, particularly India, and
the large USA market, through a mix of ingredient and finished products sold
by brand owners, specialised distributors and e-commerce channels. OptiBiotix
is now beginning to see returns from the investments made in clinical studies,
intellectual property, and more recently supporting partners in their
marketing at a time when the anti-obesity drugs have enhanced consumer
awareness of the benefits of appetite suppression in weight management.  We
are now seeing regular launches of SlimBiome® products with larger partners
in more countries around the world, enhancing brand recognition and creating
greater interest.  The focus now is on increasing the number of large
partners and delivering regular repeat orders to reach group profitability.

 

Stephen O'Hara, CEO of OptiBiotix Health plc said: "We are pleased to announce
the launch of SlimBiome® containing products with a well-known global brand
like NHT.  TwinSlim Tomato soup was developed specifically for NHT to create
a healthy snack which reduces hunger and food cravings and meets the needs of
Asian and US markets and extends the range of products containing
SlimBiome® in the USA and Asia markets. This is part of a growing trend to
incorporate science backed functional ingredients into everyday products."

 

"As the dynamics continue to change in the weight management industry, brought
about by the anti-obesity drugs, SlimBiome®'s IP and human studies are
meeting a developing market need for added functionality in weight management
products. More specifically, following the launch of the anti-obesity drugs,
natural non-drug alternatives to reduce hunger and cravings are actively being
sought by consumers. This announcement demonstrates that the science and
multiple human studies carried out on SlimBiome® is now attracting the
interest of well-known health brands around the world."

 

The Directors of the Company are responsible for the release of this
announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                          www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman                                                  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)           Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Peterhouse Capital Limited (Broker)            Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd
 Anna Dunphy                                    Mob: 07876 741 001

 

 

 

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements.
These forward-looking statements are not historical facts but rather are based
on the Company's current expectations, estimates, and projections about its
industry; its beliefs; and assumptions. Words such as 'anticipates,'
'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject to known
and unknown risks, uncertainties, and other factors, some of which are beyond
the Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in the
forward-looking statements. The Company cautions security holders and
prospective security holders not to place undue reliance on these
forward-looking statements, which reflect the view of the Company only as of
the date of this announcement. The forward-looking statements made in this
announcement relate only to events as of the date on which the statements are
made. The Company will not undertake any obligation to release publicly any
revisions or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of this
announcement except as required by law or by any appropriate regulatory
authority.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUKSNRVUUVAAR